Flyte Hops: Vision Jet Platform Seeks to Redefine Private Aviation
Rhea-AI Summary
Catheter Precision (NYSE American: VTAK) subsidiary Fly Flyte announced expansion of its Vision Jet-powered Hops short‑haul regional platform, operating three aircraft today with two additional Vision Jets under accepted bids and expected to be fully operational by Memorial Day 2026.
The Hops model targets flights under ~500 miles, offering private‑terminal access, rapid booking‑to‑boarding, AI-driven scheduling/pricing, right‑sized economics, and safety features (CAPS, Safe Return) to enable high‑frequency regional travel.
Positive
- Fleet expansion to five Vision Jets expected by Memorial Day 2026
- Platform focused on short‑haul flights under ~500 miles
- AI-driven scheduling and pricing to improve fleet utilization
- Safety features highlighted: CAPS and Safe Return emergency auto‑land
Negative
- Operates only three aircraft today, indicating limited current scale
- Two additional Vision Jets are under accepted bids but not yet operational
News Market Reaction – VTAK
On the day this news was published, VTAK declined 4.17%, reflecting a moderate negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
VTAK’s modest 0.84% gain occurred alongside mixed moves in peers: NUWE and BJDX rose, BBLG and NAOV fell, and VERO gained 8.28%. No peers appeared in the momentum scanner, pointing to a stock‑specific narrative rather than a clear sector rotation.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Mar 16 | Route expansion | Positive | +4.4% | Launch of Flyte Hops Florida with strong initial bookings and fleet growth plans. |
| Mar 11 | Financing & acquisition | Positive | -7.0% | Institutional financing commitments up to $88M and completion of Flyte acquisition. |
| Mar 10 | Acquisition close | Positive | +25.6% | Acquisition of remaining 80.02% of Fly Flyte, consolidating aviation platform. |
| Mar 06 | Product visibility | Positive | -2.1% | LockeT device featured in live cases at ISLAA 2026 medical meeting. |
| Feb 19 | Asset divestiture | Positive | -6.5% | Sale of atherectomy catheter assets for cash, equity stake and long‑term royalties. |
Recent news has often been positive, but price reactions skew mixed, with several dilution/financing or strategic updates followed by negative moves despite constructive narratives.
Over the last six weeks, VTAK has shifted from legacy medical devices toward a regional aviation platform via Flyte. On Feb 19, it sold non‑core atherectomy assets for cash, equity, and a 10‑year royalty. Early February and March 8‑K filings detailed complex preferred financings and partial Flyte acquisitions, followed by a definitive deal on Mar 10 and up to $88 million in institutional commitments on Mar 11. The Mar 16 Flyte Hops Florida launch highlighted strong early bookings. Today’s fleet‑expansion update continues this aviation‑growth storyline.
Market Pulse Summary
This announcement underscores Flyte’s push to expand its Cirrus Vision Jet fleet and build a high‑frequency network for flights under about 500 miles, emphasizing safety features like CAPS and Safe Return auto‑land. It follows recent financings and acquisitions that consolidated Flyte within VTAK and funded growth. Investors evaluating this shift may track fleet deployment by Memorial Day 2026, demand trends on new routes, and how capital structure changes described in recent proxies and 8‑K filings affect long‑term flexibility.
Key Terms
fbo technical
ai-driven scheduling and pricing optimization technical
cirrus airframe parachute system (caps) technical
safe return™ emergency auto-land technical
garmin avionics technical
flight envelope protection systems technical
AI-generated analysis. Not financial advice.
Hops Scalable Vision Jet Fleet Expansion Unlocking High-Frequency Short-Haul Regional Travel
Flyte’s Vision Jet-Powered Hops Platform Aims to Establish a New Standard in Regional Travel with Industry-Leading Safety, Speed, Efficiency and Affordability
FORT MILL, S.C., March 25, 2026 (GLOBE NEWSWIRE) -- Catheter Precision, Inc. (NYSE American: VTAK) and its wholly-owned subsidiary Fly Flyte, Inc. (“Flyte”), today announced the expansion of its Vision Jet-powered Hops platform, a scalable short-haul regional travel solution designed to deliver faster, safer, and more affordable private aviation than competitors. Flyte currently operates three aircraft, with two additional Vision Jets under accepted bids and expected to be fully operational by Memorial Day 2026 to meet accelerating inbound demand.
Flyte’s Hops platform is built around the Cirrus Vision Jet, single-engine private jet purpose-built for luxurious high-frequency regional travel. By aligning aircraft capability with actual mission demand, Flyte believes it is establishing a new category within private aviation focused on efficiency, accessibility, and safety without compromising the premium travel experience.
Flyte Hops - A Structural Shift in Private Aviation
Flyte Hops is purpose-built for flights under approximately 500 miles, a segment where traditional private aviation is often inefficient and cost-prohibitive to operate.
The Hops platform delivers:
- Private terminal access (FBOs), eliminating TSA delays and significantly reducing total travel time
- Rapid booking-to-boarding timelines, enabling near on-demand regional travel
- Right-sized aircraft economics, driving materially lower operating costs versus larger jets
- High-frequency route capability, supporting repeatable and scalable short-haul travel
- AI-driven scheduling and pricing optimization, improving fleet utilization and customer experience
- This model seeks to transform private aviation from a discretionary luxury into a practical, time-efficient regional transportation solution.
Flyte Hops - Competitive Positioning
Unlike legacy charter operators built around larger aircraft and longer-haul missions, Flyte’s Hops platform is optimized for:
- Short-haul, high-frequency travel
- Lower cost per flight hour
- Faster turnaround and higher asset utilization
- Scalable regional network expansion
- This structural advantage should enable Flyte to deliver superior customer experience while maintaining strong unit economics.
Flyte Hops - Growth Strategy
Flyte is actively expanding its Vision Jet fleet and geographic footprint, targeting high-density regional travel corridors across the United States.
Flyte’s strategy includes:
- Fleet expansion aligned with demand growth
- Development of high-frequency regional routes
- Continued investment in AI-driven operations and pricing
- Strategic partnerships to accelerate customer acquisition
Vision Jet - Safety as a Core Differentiator
Vision Jet introduces advanced safety technologies that meaningfully differentiate Flyte from traditional charter operators.
Key features include:
- Cirrus Airframe Parachute System (CAPS), the only full-aircraft parachute system in private jet aviation, capable of safely lowering the entire aircraft in an emergency
- Safe Return™ Emergency Auto-land, enabling fully autonomous navigation and landing at the push of a button
- Advanced Garmin avionics and integrated auto throttle systems, reducing pilot workload and enhancing operational precision
- Enhanced vision and flight envelope protection systems, improving situational awareness and reducing risk
About Flyte
Flyte is a technology-enabled Regional Air Mobility Company operating a growing fleet of Cirrus Vision Jets. Focused on high frequency, short haul markets, Flyte provides a faster, safer, and more efficient alternative to traditional private charter travel.
Flight operations are conducted through Flyte’s wholly owned subsidiary, Ponderosa Air, LLC, an FAA certified Part 135 air carrier. With certified aircraft, active revenue generating operations, and scalable fleet expansion underway, Flyte is building disciplined, asset backed aviation infrastructure designed to serve underserved regional markets.
For more information, visit www.flyte.travel
About Catheter Precision
Catheter Precision is an innovative U.S.-based medical device company bringing new solutions to market to improve the treatment of cardiac arrhythmias. It is focused on developing groundbreaking technology for electrophysiology procedures by collaborating with physicians and continuously advancing its products.
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements preceded by, followed by or that otherwise include the words “believe,” “anticipate,” “estimate,” “expect,” “focus,” “intend,” “plan,” “potential,” “project,” “prospects,” “outlook,” and similar words or expressions, or future or conditional verbs, such as “will,” “should,” “lends,” “would,” “may,” and “could,” are generally forward-looking in nature and not historical facts, including, without limitation, Flyte’s seeking to redefine private aviation, Flyte’s aim to establish a new standard in regional travel with industry-leading safety, speed, efficiency and affordability, Flyte’s expectation that two additional Vision Jets will be fully operational by Memorial Day, Flyte’s belief it is establishing a new category within private aviation focused on efficiency, accessibility, and safety without compromising the premium travel experience, Flyte’s seeking to transform private aviation from a discretionary luxury into a practical, time-efficient regional transportation solution, and Flyte’s structural advantage should enable Flyte to deliver superior customer experience while maintaining strong unit economics. These forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the Company's actual results, performance, or achievements to be materially different from any anticipated results, performance, or achievements for many reasons. Unless otherwise required by law, the Company disclaims any intention to, and undertakes no obligation to, revise any forward-looking statements, whether because of new information, a future event, or otherwise and such statements are made only as of the date hereof. For additional risks and uncertainties that could impact the Company's forward-looking statements, please see the Company's Form 10-K and Form 10-Q’s, including but not limited to the discussion under “Risk Factors” therein, which the Company has filed with the SEC and which may be viewed at www.sec.gov.
CONTACTS:
Investor Relations
973-691-2000
IR@catheterprecision.com
# # #
FAQ
How many aircraft does Fly Flyte (VTAK) operate and when will fleet expand?
What routes and distances does Flyte Hops (VTAK) target for regional travel?
What safety technologies differentiate Flyte Hops (VTAK) Vision Jet operations?
How does Flyte Hops (VTAK) aim to reduce travel time versus traditional private aviation?
What role does AI play in Flyte Hops (VTAK) operations and pricing?